Skip to main content

Table 1 Patients demographic, functional, treatment and blood characteristics

From: Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis

  Healthy subjects n = 55 Untreated IPF n = 24 Treated IPF n = 26
Age, yrs 60 (8) 74 (9)*** 68 (9)***
Gender (M/F) 28/27 19/5 16/3
Height, cm 170 (8) 168 (10) 170 (9)
Weight, Kg 75 (12) 74 (16) 78 (11)
BMI, Kg/m2 26 (3) 26 (4) 27 (3)
Smokers (NS/FS/S) 23/22/6 3/8/6 (6/19/0)
Leucocytes x103/μl 7.00 (5.39) 8.35 (2.35)* 8.42 (2.91)**
Neutrophils (Cell/μl) 3450 (1025) 5614 (2113)*** 5960 (3053)***
Lymphocytes (Cell/μl) 2085 (620) 1676 (825)* 1786 (643)
Monocytes (Cell/μl) 486 (160) 698 (325)** 725 (218)***
Eosinophils (Cell/μl) 173 (125) 314 (266)** 214 (128)
Basophils (Cell/μl) 33 (17) 55 (67) 94 (187)
Fibrinogen (g/l) 3 (0.80) a4 (1.40)*** nd
CRP (mg/l) 1.9 (2.89) a30 (37.89)*** nd
FEV1 post-BD, %pred. 105 (12) 75 (14)*** 67 (13)***
FVC post-BD, %pred. 111 (16) 73 (14)*** 66 (16)***
TLC, %pred. nd 71 (19) 68 (15)
DLCO %pred. nd 37 (11) 38 (13)
KCO %pred. nd 63 (16) 70 (20)
Treatment (pirfenidone/nintedanib) 0/0 0/0 17/9
Pirfenidone (duration of treatment -Month) nd nd 9.9 (7.4)
Nintedanib (duration of treatment -Month) nd nd 14.3 (15.8)
  1. nd not determined
  2. Data are expressed as mean (SD)
  3. Non smoker (NS), former smoker (FS), smoker (S)
  4. *p < 0.05 **p < 0.001 ***p < 0.0001 compared to healthy subjects
  5. an = 13